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STATE OF THE ART
Bone marrow processing practices are well established in cell processing facilities [1] .
However, these practices remain heterogeneous and are based on scarce publications and mostly single-center results. Availability of automatic devices is usually limited in each center and evolving, with some well-established devices getting withdrawn from the market, while new devices are coming into the market.
In addition, testing and quality control methods are improving, thus creating the need to revise established thresholds and release criteria.
METHODOLOGY
To evaluate practices, we conducted a survey to French speaking cell processing laboratories regarding bone marrow processing techniques. We received 23 responses: main results are summarized in Tables 1-5. 
Release criteria
In case of minor ABO blood group incompatibility each processing facility should validate its own release threshold of acceptable anti-A and/or anti-B antibodies titers.
In case of major ABO incompatibility, residual red blood cells should not exceed a threshold of 0,2 mL/kg at the time of graft release. In case of bidirectional ABO incompatibility, both of the above mentioned criteria should be met.
Of note:
* The volume of the infused cell product should not exceed 20 mL/kg, depending on the clinical status of the recipient (cardiac status and kidney function, to be discussed with the clinician). For example, in the allogeneic setting with ABO identity and donor /recipient weight imbalance (i.e. adult donor/child recipient), plasma removal, buffy coat preparation or erythrocyte depletion can be used to reduce the bone marrow volume before infusion and to not surpass the limit mentioned above.
* After processing and adequate quality controls, the bone marrow graft should be delivered 
ISSUES TO BE ADDRESSED IN THE FUTURE
-Given the heterogeneity of anticoagulation harvesting methods, harmonization of bone marrow harvesting procedures is needed.
-Harmonization of hematopoietic stem cell graft washing procedures after thawing is necessary.
-A multicenter study would be helpful to evaluate the efficiency of new automatic devices for red blood cell bone marrow depletion.
-A multi-centric study aimed at determining bone marrow CD34+ cell target dose (using single platform technique) is of interest.
-Techniques and threshold for anti-A and anti-B antibody titration should be harmonized between immuno-hematology laboratories. To begin with, at least each center should define its own internal standards.
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